ClinicalTrials.gg
Active, not recruitingNCT05700708Updated Nov 13, 2026

Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites

An observational study in Cirrhosis, Liver, Acute-On-Chronic Liver Failure and Refractory Ascites, sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh. Active, not recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Post Graduate Institute of Medical Education and Research, Chandigarh · Observational

Updated Nov 13, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh — 4 open to participants now, 6 under way, none of them phase 3. Liver Cirrhosis · Post Graduate Institute of Medical Education and Research, Chandigarh.

Started
2022
with 1 other
Observational
7 of 17
1 open now
Registered
14th of 17
by date

Among the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, this one is one of 2 that started in 2022, is one of 7 observational ones, and was the 14th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

4 of the 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Liver Cirrhosis by Post Graduate Institute of Medical Education and Research, Chandigarh, or all of them as a file.
02

Study summary

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately.

We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) \& cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and Refractory Ascites.

Read the detailed description

The decrease in systemic vascular resistance (SVR) and redistribution of blood volume with reduced intravascular volume compartment and third space fluid losses. Systemic vasodilatation is compensated by an increase in cardiac output (CO) in the initial stages of compensated cirrhosis. However, as the stage of liver cirrhosis progresses to decompensation, more prominent arterial vasodilatation and reduced SVR leads to a fall in CO. Thus, the cardiac homeostat is reset in a cirrhotic hyperdynamic circulation, wherein an increased heart rate, and therefore, increased cardiac output will no longer be able to compensate for the reduced mean arterial pressure (MAP), and decreased blood volumes in central venous territories.18 Consequent activation of vasoconstrictor systems including renin-angiotensin-aldosterone, vasopressin and the sympathetic nervous system comes into play to maintain the intravascular blood volume and pressure. These compensatory pathways cause an increase in sodium and water retention resulting in refractory ascites and hepatorenal syndrome (HRS). In critically ill patients with cirrhosis, the limited cardiac reserve is further stressed, CCM and heart failure may be diagnosed for the first time when the patient develops sepsis or septic shock.

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis accurately. We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) \& cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) in patients with cirrhosis ACLF and refractory ascites

Definition of CCM is as per updated CCMC criteria of 2020.

03

Conditions studied

  • Cirrhosis, Liver
  • Acute-On-Chronic Liver Failure
  • Refractory Ascites
  • Ascites
  • Acute Kidney Injury

Keywords

  • Ascites
  • Cirrhotic Cardiomyopathy
  • Acute kidney injury
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cirrhosis of any etiology, aged between 18-65 years, with Refractory Ascites definition as per International Ascites club.

  1. Diuretic-resistant ascites
  2. Diuretic-intractable ascites

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cirrhosis of any Etiology
  • Patient with Ascites

Exclusion criteria

Exclusion Criteria:

  • Hepatocellular carcinoma
  • Patients with active variceal bleeding
  • or severe state
  • Chronic kidney disease (CKD) on renal replacement therapy (RRT),
  • Previous transjugular intra hepatic portosystemic shunt (TIPS)
  • Porto-pulmonary hypertension,
  • Coronary artery disease
  • Congenital or valvular heart disease
  • Prosthetic cardiac valves
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cirrhosis with Refractory Ascites

    Diagnostic Test: Echocardiographic assessment

Interventions

  • Diagnostic testEchocardiographic assessment

    POC-Echocardiography to assess dynamic changes in cardiac output to assess therapeutic responses with albumin, midodrine, diuretics and domiciliary albumin

06

What researchers measure

Primary outcomes

  1. Cardiac output measurement by echocardiography after albumin

    Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000

    Time frame: Day 0

  2. Cardiac output measurement by echocardiography after albumin

    Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000

    Time frame: Day 1

  3. Cardiac output measurement by echocardiography after albumin

    Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000

    Time frame: Day 2

  4. Cardiac output measurement by echocardiography after albumin

    Echocardiographic assessment of cardiac output in L/min will be recorded at least 3 time points, day 0, day 1 and day 2. The cardiac output at 3 days after enrollment and albumin therapy will also be documented. The Doppler velocity time integral (VTI) method in estimating stroke volume and cardiac output correlates well with results of concurrent thermodilution cardiac output determinations in patients without significant left-sided valvular regurgitation. Cardiac output(CO), Stroke volume (SV), Heart rate (HR) CO = \[SV \* HR\]/ 1000

    Time frame: Day 3

Secondary outcomes

  1. Change in Cystatin C and Neutrophil gelatinase associated lipocalin (NGAL) level

    Time frame: day 0

  2. Change in NT Pro brain natriuretic peptide (BNP) level

    Time frame: day 0

  3. Change in plasma renin activity level

    Time frame: day 0

  4. Change in Galectin-3 level

    Time frame: day 0

  5. IVC size and collapsibility changes after 20% albumin

    IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.

    Time frame: Day 0

  6. IVC size and collapsibility changes after 20% albumin

    IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.

    Time frame: Day 2

  7. Lung Ultrasound score change after 20% Albumin

    Time frame: Day 1

  8. IVC size and collapsibility changes after 20% albumin

    IVC maximum and Minimum diameter and collapsibility index determined by percentage change in IVC diameter will be recorded.

    Time frame: Day 1

  9. Lung Ultrasound score change after 20% Albumin

    Time frame: Day 0

  10. Lung Ultrasound score change after 20% Albumin

    Time frame: Day 2

07

Study locations

1 site
08

References and documents

Publications

  • Adebayo D, Neong SF, Wong F. Refractory Ascites in Liver Cirrhosis. Am J Gastroenterol. 2019 Jan;114(1):40-47. doi: 10.1038/s41395-018-0185-6. PubMed 29973706 ↗
  • Larrue H, Vinel JP, Bureau C. Management of Severe and Refractory Ascites. Clin Liver Dis. 2021 May;25(2):431-440. doi: 10.1016/j.cld.2021.01.010. Epub 2021 Mar 11. PubMed 33838859 ↗
  • Cardenas A, Arroyo V. Refractory ascites. Dig Dis. 2005;23(1):30-8. doi: 10.1159/000084723. PubMed 15920323 ↗
  • Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010 Aug;30(7):937-47. doi: 10.1111/j.1478-3231.2010.02272.x. Epub 2010 May 21. PubMed 20492521 ↗
  • Izzy M, VanWagner LB, Lin G, Altieri M, Findlay JY, Oh JK, Watt KD, Lee SS; Cirrhotic Cardiomyopathy Consortium. Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology. 2020 Jan;71(1):334-345. doi: 10.1002/hep.30875. Epub 2019 Oct 11. PubMed 31342529 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Oct 2026, 47 months.

Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's 47 months is close to that.

Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Nov 2023 → Oct 2026 and completion Jul 2024 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Jan 26, 2023
StartActual
Nov 15, 2022
Primary completionActual
Oct 15, 2026was Nov 2023
CompletionEst.
Jun 15, 2027was Jul 2024
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • PGIMER · Chandigarh, India
Show 1 removed
  • PGIMER · Chandigarh, India
Nov 13, 2026
Primary completion
Nov 15, 2023→Oct 15, 2026 (actual)
Nov 13, 2026
Study completion
Jul 15, 2024→Jun 15, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • PGIMER · Chandigarh, India
    Show 1 removed
    • PGIMER · Chandigarh, India
    Primary completion Nov 15, 2023→Oct 15, 2026 (now actual)
    Study completion Jul 15, 2024→Jun 15, 2027
    + 4 other changes: identifiers, verification date, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05700708
Responsible party
Madhumita Premkumar (Associate Professor, Post Graduate Institute of Medical Education and Research, Chandigarh) — Principal investigator
First posted
Jan 26, 2023
Start date
Nov 15, 2022
Primary completion
Oct 15, 2026
Completion
Jun 15, 2027 (estimated)
Last update
Nov 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion